IMNM logo

IMMUNOME INC

IMNMNASDAQ
🏆 #1832 by market capUS Equity
$18.29▼ $0.47 (−2.53%)
Market closed · at close
🔔
Track IMNM
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.5%
7d▲ 1.6%
14d▲ 11.0%
30d▼ 15.1%
ytd▼ 15.0%
1y▲ 14.7%
🏦Market Cap
$2.16B
Small Cap
📈Revenue Growth (YoY)
-23.2%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
36
Weak

Trading Snapshot

Day Range
$18.11 – $19.27
52-Week Range
$14.64 – $30.06
Volume (shares)
59,010
Avg Volume (shares)
—
Shares Outstanding
118.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$7M
Last Q Revenue
—
P/E Ratio
-7.4
P/S Ratio
0.0x
EPS (TTM)
$-2.25
Dividend Yield
0.00%
Dilution (1yr)
+39.3%
IMNM logo

IMMUNOME INC

IMNM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$7M▼ −23.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.4%▼ −42.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$214M▼ −30.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$201M▲ +22.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
87.4M▲ +39.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$650M▲ +$511M YoY
StockOtter · stockotter.space

About IMMUNOME INC

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100
Analyst data unavailable.

Latest News & Updates

News unavailable.